NCT06284564 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06284564
Title	A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	M.D. Anderson Cancer Center
Indications	renal cell carcinoma
Therapies	Evolocumab + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
UT Southwestern Medical Center		Dallas	Texas	75390	United States	Details
MD Anderson Cancer Center		Houston	Texas	77030	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06284564Clinical Trial Detail